Central Pacific Bank Trust Division Acquires Shares of 116 STERIS plc (NYSE:STE)

Central Pacific Bank Trust Division purchased a new stake in STERIS plc (NYSE:STE) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 116 shares of the medical equipment provider’s stock, valued at approximately $28,000.

Several other institutional investors also recently bought and sold shares of the business. J.Safra Asset Management Corp grew its position in shares of STERIS by 77.9% in the first quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 53 shares during the period. Quent Capital LLC boosted its position in STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 71 shares during the last quarter. Headlands Technologies LLC purchased a new stake in STERIS during the 1st quarter valued at about $36,000. Versant Capital Management Inc raised its holdings in STERIS by 2,262.5% in the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after acquiring an additional 181 shares during the last quarter. Finally, Brown Brothers Harriman & Co. lifted its stake in STERIS by 154.7% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 116 shares in the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on STE. StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a report on Tuesday, August 13th. JMP Securities reiterated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a report on Wednesday, August 7th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Thursday, August 8th. Stephens restated an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. Finally, KeyCorp boosted their target price on shares of STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $246.00.

Insider Buying and Selling at STERIS

In related news, Director Christopher S. Holland sold 473 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the transaction, the director now directly owns 582 shares of the company’s stock, valued at $139,493.76. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the transaction, the director now directly owns 582 shares in the company, valued at $139,493.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

STERIS Stock Down 0.8 %

Shares of STE stock traded down $1.84 during trading on Friday, reaching $231.02. The company’s stock had a trading volume of 378,390 shares, compared to its average volume of 445,579. STERIS plc has a 1-year low of $195.47 and a 1-year high of $248.24. The stock’s 50-day moving average price is $238.01 and its 200 day moving average price is $225.89. The company has a market capitalization of $22.78 billion, a price-to-earnings ratio of 60.48 and a beta of 0.84. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49.

STERIS (NYSE:STE) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the company earned $2.00 EPS. STERIS’s revenue for the quarter was down .4% compared to the same quarter last year. On average, research analysts anticipate that STERIS plc will post 9.06 EPS for the current year.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 20th. Investors of record on Thursday, September 5th were issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 0.99%. This is an increase from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. STERIS’s dividend payout ratio is 59.69%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.